Novo Nordisk fights back with oral GLP-1 data in obesity Shortly after reporting weaker-than-expected sales of its injectable GLP-1 drugs, Novo Nordisk revealed clinical results with an oral alternative that suggest it can offer comparable efficacy with convenient, daily dosing
[DOI] [PMC free article] [PubMed] [Google Scholar] Som S, Raha C, Chatterjee IB
More serious reactions are rare but require medical attention
A study of more than 400,000 posts in the social media platform Reddit has identified previously unreported side effects from the increasingly popular GLP-1 weight loss and diabetes drugs
It is particularly popular in fitness and bodybuilding research for its ability to enhance muscle growth, improve muscle recovery, and support fat metabolism
Both of these drugs may help people lose weight but the ways they work on the body are different